Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TB Alliance, a non-profit product development partnership for new tuberculosis (TB) drugs, has announced the signing of four drug discovery collaboration agreements. All four projects for drug discovery for TB have the potential to produce compounds effective against drug resistance tuberculosis and show promise to advance the science of TB drug development.
Subscribe to our email newsletter
Dr. Mel Spigelman, CEO of TB Alliance, said: “These partnerships show that the TB Alliance is aggressively increasing the depth and strength of its portfolio to ensure that promising new TB drug candidates continue moving toward the clinic.
“Tuberculosis is responsible for the death of one person approximately every 20 seconds and there is a significant need for novel medications to combat growing bacterial resistance to current drugs and to reduce the duration and complexity of therapy,” he added.